Journal
JOURNAL OF NEUROSCIENCE
Volume 36, Issue 13, Pages 3777-3788Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.0451-15.2016
Keywords
systemic inflammation; temporal lobe epilepsy; CCL2; EEG; seizures
Categories
Funding
- Italian Ministry of Health [RF-TAA-2008-1141282]
- Fondazione Pisa Grant [158/2011]
- Accademia dei Lincei (Rome, Italy)
- Fondazione Veronesi (Milan, Italy)
Ask authors/readers for more resources
Epilepsy is a chronic disorder characterized by spontaneous recurrent seizures. Brain inflammation is increasingly recognized as a critical factor for seizure precipitation, but the molecular mediators of such proconvulsant effects are only partly understood. The chemokine CCL2 is one of the most elevated inflammatory mediators in patients with pharmacoresistent epilepsy, but its contribution to seizure generation remains unexplored. Here, we show, for the first time, a crucial role for CCL2 and its receptor CCR2 in seizure control. We imposed a systemic inflammatory challenge via lipopolysaccharide (LPS) administration in mice with mesial temporal lobe epilepsy. We found that LPS dramatically increased seizure frequency and upregulated the expression of many inflammatory proteins, including CCL2. To test the proconvulsant role of CCL2, we administered systemically either a CCL2 transcription inhibitor (bindarit) or a selective antagonist of the CCR2 receptor (RS102895). We found that interference with CCL2 signaling potently suppressed LPS-induced seizures. Intracerebral administration of anti-CCL2 antibodies also abrogated LPS-mediated seizure enhancement in chronically epileptic animals. Our results reveal that CCL2 is a key mediator in the molecular pathways that link peripheral inflammation with neuronal hyperexcitability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available